Learn more about a topical JAK inhibitor for atopic dermatitis from dermatologist Dr. Ashley Sutherland
ESC asked dermatologist Ashley Sutherland, MD, MSc, FRCPC, to share her expertise on the topical JAK inhibitor Opzelura® (ruxolitinib) and how this medication is used to manage atopic dermatitis (AD), the most common form of eczema.
What are topical JAK inhibitors?
Topical Janus kinase (JAK) inhibitors are non-steroidal creams used for treating mild to moderate AD for those who haven’t found success, or it isn’t recommended to use other topical treatments (topical corticosteroids, topical calcineurin inhibitors). Topical JAK inhibitors help block many of the molecules, called cytokines, that worsen the inflammation and itch.
How does Opzelura® work?
Opzelura® works by targeting the JAK-STAT pathway in the skin, which causes AD symptoms. It works by blocking many of the molecules, called cytokines, that worsen the inflammation and itch.1
Who is Opzelura® approved for?
Opzelura® is used on the skin (topical) to treat patients aged 12 years and older with mild to moderate atopic dermatitis, also known as eczema. It is used when treatment with other topical prescription medicines have not worked well or have not been tolerated well, or when those medicines should not be used.1
How is Opzelura® used?
Opzelura® is a cream that is applied directly to the skin. It is indicated as safe for use on all skin surfaces. However, it should not be applied directly into the eyes, mouth, or vagina. Do not apply to the lips to avoid swallowing it by accident.
Opzelura® is typically applied to the skin two times daily during the periods of flare until the skin improves. However, patients should use this medication as prescribed by their health care professional.
What are the side effects of this medication?
Possible side effects may include the common cold, headache, influenza, and fever. You may experience the following side effects on the area where you applied Opzelura®: acne, pain, such as a burning or stinging sensation, itching, redness, rash, and mild peeling.
Topical JAK inhibitors also come with a Serious Warnings and Precautions box (a ‘boxed’ or ‘black box’ warning can be found on prescription medications, depending on the side effects) based on types of events that have been reported with a drug that belongs in the same class of medicines (JAK inhibitors) but taken by mouth. This other drug is used to treat a type of arthritis for which topical JAK inhibitors are not used. All medications have risks and benefits, and the details of the risks and benefits should be reviewed with the prescribing health care professional. Consult your health care professional to determine if this medication is right for you.
What if my atopic dermatitis does not get better?
If you find your AD isn’t responding to treatment, let your doctor know, as your treatment plan may need to be adjusted. A qualified health care professional, such as a dermatologist, can help reassess your or your child’s condition and can potentially adjust the treatment plan. There is no cure for AD, but there are now many treatments that can help patients.
Eczema Society of Canada thanks Ashley Sutherland, MD, MSc, FRCPC, for her volunteer contribution to this educational content.
Reference: 1 Incyte Corporation (October 2024). Opzelura® (ruxolitinib) [Product Monograph], Topical Janus Kinase (JAK) Inhibitor.
Disclaimer: Information provided in this resource does not constitute medical advice and is not intended to be used as a diagnostic tool. The information is up-to-date at the time of publication. All medications, interventions, and treatment plans have risks and benefits, and it is important that individuals discuss their or their child’s specific health care needs with a qualified health care professional.
